- 1.
Sørensen H, Fadl Elmula FEM, Kjeldsen SE et al. Renal sympatisk denervering ved terapiresistent hypertensjon. Tidsskr Nor Legeforen 2014; 134: 32–6. [PubMed][CrossRef]
- 2.
Fadl Elmula FEM, Hoffmann P, Fossum E et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62: 526–32. [PubMed][CrossRef]
- 3.
Fadl Elmula FEM, Hoffmann P, Larstorp ACK et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014; 63: 991–9. [PubMed][CrossRef]
- 4.
Persu A, Jin Y, Baelen M et al. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 2014; 63: 1319–25. [PubMed][CrossRef]
- 5.
Kjeldsen SE, Fadl Elmula FEM, Persu A. The setback of renal denervation should not backfire on sympathetic overactivity in hypertension. J Am Coll Cardiol 2015; 65: 1322–3. [PubMed][CrossRef]
- 6.
Fadl Elmula FEM, Jin Y, Yang WY et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press 2015; 24: 263–74. [PubMed][CrossRef]
- 7.
Persu A, Kjeldsen S, Staessen JA et al. Renal denervation for treatment of hypertension: a second start and new challenges. Curr Hypertens Rep 2016; 18: 6. [PubMed][CrossRef]
- 8.
Fadl Elmula FEM, Feng Y-M, Jacobs L et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Press 2017; 26: 195–203. [PubMed][CrossRef]
- 9.
Kjeldsen SE, Narkiewicz K, Burnier M et al. Take a blood pressure pill or benefit from renal denervation? Eur Heart J 2018; 39: 3010–2. [PubMed][CrossRef]
- 10.
Kjeldsen SE, Esler MD. Take a blood pressure pill or undergo renal denervation? Lancet 2018; 391: 2298–300. [PubMed][CrossRef]
- 11.
Kjeldsen SE, Fadl Elmula FEM, Persu A. Future of renal sympathetic denervation in the treatment of hypertension. J Am Coll Cardiol 2019; 73: 1643–5. [PubMed][CrossRef]
- 12.
Kjeldsen SE, Burnier M, Narkiewicz K et al. Key questions regarding the SYMPLICITY HTN-3 trial. Lancet 2023; 401: 1336–7. [PubMed][CrossRef]
- 13.
Persu A, Stoenoiu MS, Maes F et al. Late outcomes of renal denervation are more favourable than early ones: facts or fancies? Clin Kidney J 2023; 16: 2357–64. [PubMed][CrossRef]
()